Skip to main content
SpringerLink
Log in

Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety

  • Gynecologic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Initial experiences reported increased surgical morbidities in patients receiving cytoreductive surgery for colorectal cancer after bevacizumab-containing chemotherapy; however, more recent literature suggests a favorable toxicity profile in patients with advanced ovarian cancer (AOC). With the aim of providing a more objective point of view on this controversial issue, we present here a systematic literature review.

Methods

Systematic revision of the available literature was conducted using the PubMed, MEDLINE, and EMBASE electronic databases. All studies reporting safety data regarding cytoreductive surgery performed before or after bevacizumab-containing chemotherapy have been analyzed for the purposes of this study. The study has been prepared according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Results

Forty-eight studies were retrieved from the electronic databases, with 23 (47.9%) being excluded due to an unsatisfactory study design. Among the remaining 25 manuscripts, 16 did not report data regarding surgical morbidities after cytoreductive surgery, therefore only 9 studies were included in the final analysis. Overall, 198 AOC patients received bevacizumab-containing neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) in the context of five studies, among whom 21 women experienced grade 3/4 postoperative complications (10.6%), which appears to be in line with data reported in patients receiving IDS after carboplatin-paclitaxel NACT. Results from phase I–II clinical trials, and dataset analysis from GOG-0218, did not observe an increased incidence of complications in AOC patients receiving bevacizumab-containing adjuvant chemotherapy after cytoreductive surgery.

Conclusions

The incorporation of bevacizumab into first-line chemotherapy was not associated with increased morbidities before and after cytoreductive surgery in women with AOC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. IMS Health, IMS lifecycle R&D Focus: IMS Institute for healthcare informatics. 2015. http://www.imshealth.com/en/thought-leadership/ims-institute/reports/emergence-and-impact-of-pharmacy-deductibles:-implications-for-patients-in-commercial-health-plans.

  2. Petrillo M, Nero C, Amadio G, Gallo D, Fagotti A, Scambia G. Targeting the hallmarks of ovarian cancer: the big picture. Gynecol Oncol. 2016;142:176–83.

    Article  CAS  PubMed  Google Scholar 

  3. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.

    Article  CAS  PubMed  Google Scholar 

  4. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.

    Article  CAS  PubMed  Google Scholar 

  5. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Poveda AM, Selle F, Hilpert F, et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial. J Clin Oncol. 2015;33:3836–38.

    Article  CAS  PubMed  Google Scholar 

  7. Eveno C, Passot G, Goéré D, et al. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2014;21:1792–800.

    Article  PubMed  Google Scholar 

  8. Chéreau E, Lambaudie E, Houvenaeghel G. Morbidity of surgery after neoadjuvant chemotherapy including bevacizumab for advanced ovarian cancer. Int J Gynecol Cancer. 2013;23:1326–30.

    Article  PubMed  Google Scholar 

  9. Salani R, O’Malley DM, Copeland LJ, Cohn DE, Backes FJ, Fowler JM, Eisenhauer EL. Feasibility of interval cytoreduction following neoadjuvant chemotherapy with carboplatin, weekly paclitaxel, and bevacizumab for advanced ovarian cancer: a phase 1 study. Int J Gynecol Cancer. 2014;24:682–86.

    Article  PubMed  Google Scholar 

  10. Petrillo M, Paris I, Vizzielli G, et al. Neoadjuvant chemotherapy followed by maintenance therapy with or without bevacizumab in unresectable high-grade serous ovarian cancer: a case-control study. Ann Surg Oncol. 2015;22:S952–58.

    Article  PubMed  Google Scholar 

  11. Rouzier R, Gouy S, Selle F, et al. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the ANTHALYA trial. Eur J Cancer. 2017;70:133–42.

    Article  CAS  PubMed  Google Scholar 

  12. Daniele G, Lorusso D, Scambia G, et al. Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): a subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. Gynecol Oncol. 2017;144:256–59.

    Article  CAS  PubMed  Google Scholar 

  13. Duska LR, Java JJ, Cohn DE, Burger RA. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236). Gynecol Oncol. 2015;139:221–27.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Gouy S, Ferron G, Glehen O, et al. Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer. Gynecol Oncol. 2016;142:237–42.

    Article  CAS  PubMed  Google Scholar 

  15. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Sehouli J, Papanikolaou G, Braicu EI, Pietzner K, Neuhaus P, Fotopoulou C. Feasibility of surgery after systemic treatment with the humanized recombinant antibody bevacizumab in heavily pretreated patients with advanced epithelial ovarian cancer. Ann Surg Oncol. 2012;19:1326–33.

    Article  PubMed  Google Scholar 

  17. Fleming ND, Coleman RL, Tung C, Westin SN, Hu W, Sun Y, Bhosale P, Munsell MF, Sood AK. Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol. 2017;147:41–46.

    Article  CAS  PubMed  Google Scholar 

  18. Fagotti A, Vizzielli G, De Iaco P, et al. A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am J Obstet Gynecol. 2013;209:e1–11.

    Article  Google Scholar 

  19. European Medicines Agency: indications for Avastin administration. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000582/WC500029260.pdf. Accessed 25 Jun 2017.

  20. Wright AA, Bohlke K, Armstrong DK, et al. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:3460–73.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Burger RA, Brady MF, Bookman MA, et al. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2014;32:1210–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Konner JA, Grabon DM, Gerst SR, et al. Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. J Clin Oncol. 2011;29:4662–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Ceelen W, Van Nieuwenhove Y, Putte DV, Pattyn P. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Ann Surg Oncol. 2014;21:3023–28.

    Article  PubMed  Google Scholar 

  24. Onda T, Satoh T, Saito T, et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer. 2016;64:22–31.

    Article  PubMed  Google Scholar 

  25. Fagotti A, Ferrandina G, Vizzielli G, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. Eur J Cancer. 2016;59:22–33.

    Article  PubMed  Google Scholar 

  26. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.

    Article  CAS  PubMed  Google Scholar 

  27. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386:249–57.

    Article  PubMed  Google Scholar 

  28. Gueli Alletti S, Bottoni C, Fanfani F, et al. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study. Am J Obstet Gynecol. 2016;214(503):e1–e6.

    Google Scholar 

  29. Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Ann Oncol. 2016;27:114–21.

    Article  CAS  PubMed  Google Scholar 

  30. Usón PL Junior, Bugano DD, et al. Does Time-to-Chemotherapy Impact the Outcomes of Resected Ovarian Cancer? Meta-analysis of Randomized and Observational Data. Int J Gynecol Cancer. 2017;27:274–80.

    Article  Google Scholar 

  31. Stockler MR, Hilpert F, Friedlander M, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014;32:1309–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Stark D, Nankivell M, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International collaboration on ovarian neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 2013;14:236–43.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Monk BJ, Huang HQ, Burger RA, et al. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2013;128:573–78.

    Article  CAS  PubMed  Google Scholar 

  34. Wysham WZ, Schaffer EM, Coles T, Roque DR, Wheeler SB, Kim KH. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial. Gynecol Oncol. 2017;145:340–45.

    Article  CAS  PubMed  Google Scholar 

  35. Hinde S, Epstein D, Cook A, Embleton A, Perren T, Sculpher M. The cost-effectiveness of bevacizumab in advanced ovarian cancer using evidence from the ICON7 trial. Value Health. 2016;19:431–39.

    Article  PubMed  Google Scholar 

  36. Kommoss S, Winterhoff B, Oberg AL, et al. Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes. Clin Cancer Res. 2017;23:3794–801.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study was supported by an unrestricted grant provided by Roche.

Author information

Authors and Affiliations

  1. Department of Woman and Child Health, Università Cattolica del Sacro Cuore, Rome, Italy

    Marco Petrillo MD, PhD, Camilla Nero MD, Vittoria Carbone MD, Matteo Bruno MD, Giovanni Scambia MD, PhD & Anna Fagotti MD, PhD

Authors
  1. Marco Petrillo MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Camilla Nero MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vittoria Carbone MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matteo Bruno MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giovanni Scambia MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anna Fagotti MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marco Petrillo MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Petrillo, M., Nero, C., Carbone, V. et al. Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety. Ann Surg Oncol 25, 247–254 (2018). https://doi.org/10.1245/s10434-017-6235-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-017-6235-2

Keywords

Search

Navigation